Repurposing Nucleoside Reverse Transcriptase Inhibitors for Treatment of AD
Status:
Not yet recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind clinical trial of a daily oral dose of 200 mg
emtricitabine vs. placebo in 35 participants with biomarker-confirmed MCI or mild dementia
due to Alzheimer's disease. Study duration for each subject participating in the
placebo-controlled research study will be approximately 9 months (up to a 1 month Screening
Period, Baseline visit (1 month), 6 months of placebo or emtricitabine dosing, and 1 month
follow-up).
Phase:
Phase 1
Details
Lead Sponsor:
Butler Hospital
Collaborators:
Alzheimer's Association Brown University The Miriam Hospital